CAMBRIDGE, Mass., April 2 /PRNewswire-FirstCall/--
Biogen, Inc. (Nasdaq: BGEN) today announced the appointment of John W. Palmer
as Senior Vice President, Corporate Development. Mr. Palmer will supervise
the company's global business development activities. He reports to Hans
Peter Hasler, Executive Vice President, Commercial Operations.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
James C. Mullen, Biogen's President and Chief Executive Officer, said,
"Business development takes on increased importance in the highly competitive
marketplace in which biotechnology companies operate today. Biogen's
combination of financial strength, world-class resources, targeted research
focus and commercial experience makes us a desirable partner. In particular,
our expertise in biologics manufacturing and experience in registering and
marketing drugs globally are unique in the biotechnology industry. John
Palmer has done an outstanding job at Biogen for more than a decade and we are
pleased that an executive of his caliber will lead this important commercial
capability."
Mr. Palmer, 51, joined Biogen in 1989 as Director of Marketing and
Business Development. In 1993, he was named Director of Operations, leading
the U.S. and European logistical launches of Biogen's first commercial
product. In 1997, he was named Program Executive for Cardiovascular Program,
and since 1999 has served as Senior Vice President, Program Management,
overseeing all Biogen Development Programs. Before joining Biogen, Mr. Palmer
was a Marketing and Business Development Director at General Foods
Corporation. From 1980-1982, he was Founder, President and Chief Operating
Officer of Caribbean Emergency Medical Air Transport, Inc., a novel air
ambulance service operating throughout the Caribbean market. From 1979-1980,
he was a managing consultant with Strategic Planning Associates in Washington,
D.C.
Mr. Palmer received an MBA from The Wharton School, a BA in International
Finance and Psychology and a AS degree in Electrical Engineering from the
University of California at Santa Barbara. From 1972-1977 he served as an
infantry officer in the U.S. Army 101st Airborne Division.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from worldwide sales of AVONEX for
treatment of relapsing forms of multiple sclerosis, and from the sales by
licensees of a number of products. (Please see full prescribing information at
http://www.avonex.com.) Biogen's research and development activities are
focused on novel products to treat inflammatory and autoimmune diseases,
neurological diseases, cancer, fibrosis and congestive heart failure. The
Company maintains active clinical research programs in protein therapeutics,
small molecules, genomics and gene therapy. For copies of press releases and
additional information about the Company, please consult Biogen's homepage on
the World Wide Web at http://www.biogen.com.
Media Contact:
Amy McKnight
Associate Director, Public Affairs
Biogen, Inc.
Tel: (617) 679-2723
Investment Community Contact:
Elizabeth Woo
Director, Investor Relations
Biogen, Inc.
Tel: (617) 679-2822
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Media, Amy McKnight, Associate Director,
Public Affairs, +1-617-679-2723, or Investment Community,
Elizabeth Woo, Director, Investor Relations, +1-617-679-2822,
both of Biogen, Inc.
|
